Latest / Conversations with CEI / Xylazine & Medetomidine & Nitazines, Oh My! An Update on New York State’s Drug Supply
Transcript
- 0:02Welcome to the Clinical Education Initiative podcast, Conversations with CEI,
- 0:07where we feature conversations with clinical experts, their experience and insights
- 0:13on current health issues in the areas of HIV,
- 0:17primary care and prevention, sexual health,
- 0:21hepatitis C, and drug user health.
- 0:24Welcome to Conversations with CEI. My name is Lauren Walker,
- 0:27and I'm the program director for CEI's Hepatitis C and Drug User Health Center of Excellence.
- 0:32On today's episode, we'll hear from Dr. Sharon Stancliffe and Dr.
- 0:35Jennifer Love about emerging substances in the New York state drug supply,
- 0:39including an update on xylazine.
- 0:41New York drug overdose deaths and death rates are on the decline,
- 0:44but with significant disparities, and the current toxic drug supply is partially to blame.
- 0:49Harmful additives like fentanyl analogs, xylazine, and metatomidine,
- 0:53among others, have been found in cocaine, heroin, MDMA, and pressed into pills.
- 0:59Additives are undetectable by sight, taste, and smell, which increases the risk
- 1:03of overdose for people who use and may not be aware of what's in their drug supply.
- 1:07The New York State Department of Health Drug Checking Program offers people
- 1:11who use drugs timely and detailed information on the contents of their substances.
- 1:15It also shares information on the state's unregulated drug supply to inform
- 1:20clinical care, advocacy, research, and policy.
- 1:23The program has tested over 2,000 drug samples, and findings indicate a steady
- 1:27proportion of xylazine in the drug supply, as well as a recent increase in the
- 1:32percent of samples containing metatomidine, a novel powerful sedative that we'll discuss today.
- 1:37I'm honored to introduce my two guests who will help unpack all of this and
- 1:41share best practices for New York state-based clinicians to support people who use drugs.
- 1:46Our first guest, Dr. Jennifer Love, is an assistant professor of emergency medicine
- 1:50at the Icahn School of Medicine at Mount Sinai.
- 1:52Her research interests focus on improving emergency department care for people
- 1:56who use drugs, and she is currently working on studies related to xylosine-adulterated fentanyl.
- 2:02I'm also joined today by Dr. Sharon Stancliffe, Associate Medical Director for
- 2:06Harm Reduction in Healthcare at the New York State Department of Health AIDS
- 2:10Institute, and an attending physician at Project Renewal, where she provides
- 2:14care for people with opioid use disorder.
- 2:16Dr. Stancliffe has been working with people who use drugs since 1990,
- 2:20including the development of overdose prevention programs, provision of primary
- 2:24care for people who use drugs, substance use disorder treatment,
- 2:27HIV care, and harm reduction services.
- 2:30We are lucky to have you both with us.
- 2:32Welcome to the show, everyone. How is your day going today? Pretty well so far.
- 2:37So far, so good. Well, thank you again for joining me. Given that today's episode
- 2:42is a follow-up to one that you and I did together, Dr.
- 2:45Stamcliffe, in February 2023, could you kick us off with just a brief reminder
- 2:49about some of the adulterants that we commonly find in the New York drug supply?
- 2:54What do they look like? Do they have a taste or smell? Well,
- 2:57some of the most common ones right now are xylozine and, of course,
- 3:02fentanyl and its various analogs, and the one I always stumble over, metatomidine.
- 3:06So these are showing up a lot in what we're seeing.
- 3:10Fentanyl and its many analogs are synthetic opioids. They're found basically
- 3:15in everything that is sold as heroin.
- 3:18It's also found in counterfeit pills, rarely, but occasionally in stimulants,
- 3:23which of course can be a catastrophe when that happens.
- 3:27There's a lot of analogs out there, at least 80 of them reported to the nations.
- 3:32Not all are illegal because they just haven't been looked at and scheduled,
- 3:36but there are laws that may change that.
- 3:39Xylozine and metachalmadine are also found.
- 3:43These are alpha-2 adrenergic agonists. They're used basically in veterinary
- 3:48medicine as sedatives, painkillers, anesthetics, and they are not approved of for human use.
- 3:54Both of them cause extreme sedation, hypotension, and bradycardia.
- 3:59The metatomidine is a newer addition. There's a lot we don't really know about
- 4:04it yet, but it is clearly more potent and has a longer duration of action than dezylothine.
- 4:11Folks may know that xylazine has been associated with severe skin wounds,
- 4:15not related to the injection necessarily.
- 4:18We don't know yet about metatomidine, unless maybe Dr. Love has some new information.
- 4:23But we haven't seen enough of it to know that for sure.
- 4:26Can you tell by looking at your drugs these are in there? No.
- 4:29People say a lot of things about it, but you can't tell by looking or any odors.
- 4:36So there's only a few ways to
- 4:38find out if it's in there. and we'll touch a little bit on drug teching.
- 4:41And we have test strips for both xylozine and fentanyl that are widely available.
- 4:47That's a great question, Sharon, that you posed about metatomidine and its relationship to wounds.
- 4:52I think, like you said, there's really a lot that we don't know about metatomidine.
- 4:56The little that we do know from the veterinary literature suggests that there
- 5:00is some peripheral vasoconstriction in animals that receive this.
- 5:04So there could be a role that it may be involved in some wound development,
- 5:09but we just don't have enough data yet to really understand the mechanisms of
- 5:13xylosine wounds, let alone if there's a role with metatomidine there.
- 5:16I think the other important thing that we're starting to understand from the
- 5:20veterinary literature about metatomidine is that in conjunction with opioids,
- 5:25as you mentioned, given as an anesthetic in animals, it can cause severe respiratory depression.
- 5:31And so sort of as it continues to emerge as an adulterant in the opioid supply,
- 5:37we may see some of that clinical effect in our patients.
- 5:40Thanks so much. Dr. Love, I'm curious, are there other emerging substances in
- 5:44the state supply that you've identified in your research as a toxicologist that
- 5:48folks should know about?
- 5:49Yeah, I think there's two important ones to bring up. Dr. Stancliffe referenced
- 5:53the fentanyl analogs and sort of the growth of fentanyl analogs and how they're always evolving.
- 6:00Nitazines are also a novel synthetic opioid that have been linked to opioid
- 6:05overdose fatalities in different areas of the United States.
- 6:08Some ones that people may have heard about are isonitazine or protonitazine.
- 6:13They are more potent than fentanyl and heroin and some of our other opioids.
- 6:19They are reversed by naloxone. We do know that naloxone works to reverse the
- 6:24effects of them in overdose.
- 6:25However, patients may require more doses of naloxone, but that is one group
- 6:30that is sort of out there among the drug supply.
- 6:33The other adulterant that is emerging is something called BTMPS.
- 6:37It's one that has been detected in different pockets of the drug supply.
- 6:41The first location I believe it was detected was in Portland,
- 6:44Oregon, and we've seen it in places such as California, some areas of the Midwest,
- 6:49and then in New York as well.
- 6:50We don't know a lot about it. It actually was developed as a light stabilizing
- 6:55agent and was used for manufacturing and packaging of pharmaceutical agents.
- 7:00But now we've seen it sort of commingled with some of our opioids.
- 7:04It does, again, we're starting to look at animal models and how it has clinical
- 7:09effects in animal models like rats and mice in the lab where researchers are doing experiments.
- 7:15And we're starting to see like what receptors it might bind to and then try
- 7:19to understand what clinical effects it could have.
- 7:21But that data is all very, very new. And so we really don't have any ideas about
- 7:25what it potentially could be causing, if anything, in humans.
- 7:29If I could just put in a quick word about naloxone, I wanted to mention under fentanyl that, as Dr.
- 7:36Delau just said, naloxone works fine with fentanyl.
- 7:39And in fact, when we look at the carefully done studies, we're not seeing an
- 7:42increase in the number of doses needed.
- 7:45I can't speak to nidazine, which is much more rare, but we do see from work
- 7:50in New York and in Pittsburgh that the number of doses, if looked at appropriately,
- 7:55has just not gone up over time despite the ubiquitousness of fentanyl.
- 7:59People may look still very sedated with the other drugs on board,
- 8:04but if they're breathing, they're good.
- 8:06So, Dr. Stancliff, kind of a side question here, you just made me wonder,
- 8:11what would happen then if someone is experiencing an overdose with some of these other substances?
- 8:16Main substance might be opioids and they are given naloxone.
- 8:19What would happen and what would you encourage someone to do if they encounter
- 8:23someone who is experiencing an overdose?
- 8:26Well, if you are with somebody and you know what they're using and they go.
- 8:31Down, then certainly plot your naloxone if they're not alert.
- 8:36Rescue breathing or even chest compressions are a good thing to do if they're not breathing.
- 8:42Try to wait two minutes, and it's scary. I've done this. It's scary to wait
- 8:46two minutes and give more naloxone if they're not breathing.
- 8:49But if they start to be a little bit responsive, we don't need them to wake up.
- 8:53We just need them to breathe and preferably call EMS for more help.
- 8:58But they may still be very sedated. And also, no matter what else you're going
- 9:03to do, open their airway.
- 9:05If somebody's slumped and doesn't have a very good respiratory drive,
- 9:08even if the respiratory drive is there, they may not be able to get the oxygen
- 9:12in. So just one additional point about naloxone.
- 9:15I think a really important epidemiologic trend that we're seeing with all of
- 9:20these new substances, xylazine, metatomidine, BTMPS, is that they're all in
- 9:26the presence of an opioid, which is largely fentanyl right now.
- 9:29We're not seeing really any of these in isolation.
- 9:32People are not accessing them and using them in isolation and overdosing on
- 9:37them in isolation. They're really always co-located with fentanyl.
- 9:41And so in that situation, as Dr.
- 9:44Stancliffe said, naloxone will work. It will save the person's life because
- 9:48you are largely reversing the effect of the opioid.
- 9:52That's most of what somebody is being exposed to. And the adulterant is having
- 9:56additional side effects, but the thing that will be life-saving for them is
- 10:00receiving the naloxone.
- 10:02Thanks, Jennifer. I want to pause here for just a minute, if I can,
- 10:05to give our audience a brief introduction to the New York State Department of
- 10:08Health Drug Checking Program and the two services that they offer.
- 10:12Before I dive into details, it's really important to point out that the program
- 10:16is not affiliated with law enforcement, nor is it ever used for any punitive action.
- 10:21So the program allows individuals to have their drugs analyzed to identify the
- 10:25composition of the substance or substances they're intending to take or have already taken.
- 10:30Here in New York, we have community drug checking through point-of-care mass
- 10:33spectrometry technology at six drug user health hubs across the state.
- 10:38We also have RADAR, that stands for Rapid Drug Analysis and Research,
- 10:42which involves partnerships with local health departments and others to support
- 10:46mail-based drug checking.
- 10:48New York City also has its own program, and I won't get into too much here except
- 10:52to say that it was the first of its kind in the United States,
- 10:55and it served as a rough guide for the statewide drug checking efforts that we have today.
- 10:59They developed a wonderful toolkit. It's called Setting Up a Drug Checking Program,
- 11:04a Comprehensive Guide, that I highly, highly recommend for programs interested
- 11:08in setting up drug checking that's linked in the resources for this podcast.
- 11:13We'll get back to all of that in just a minute, but I want to bring the conversation
- 11:16back to the clinical aspects of these additives first.
- 11:20So Jennifer, we know that xylazine is approved only for use in veterinary medicine,
- 11:25and I'm wondering, what about the other substances we've been talking about today?
- 11:30Do any of them have clinical purposes beyond animal medicine?
- 11:34Yeah, so as of right now, all of these are restricted to veterinary use for
- 11:40xylazine and menetomidine.
- 11:42Xylazine and menetomidine, as Dr. Stancliff pointed out, they are within a drug
- 11:45class called alpha-2 adrenergic agonists.
- 11:48And so we have some medications that are approved for human use that fall within
- 11:54that class, and that's sort of how we try to understand the effects that these
- 11:58adulterians might have.
- 11:59Those two drugs are clonidine, which is an anti-hypertensive medication that
- 12:03a lot of people may be prescribed or prescribe in their practice.
- 12:07The other one is something called dexmedetomidine, which is an anesthetic used
- 12:11largely in the ICU, sometimes in the emergency department for patients needing anesthesia.
- 12:16But xylazine and metetomidine themselves are still restricted to veterinary use.
- 12:20Analogs the nitazines btmps those are all very very new again have really no
- 12:26human use aren't really having any known sort of veterinary use either to my
- 12:32knowledge but are sort of just evolved in a chemical way that they are becoming
- 12:38more available in the opioid supply
- 12:40So as you're seeing some of these substances more regularly in the supply in
- 12:45New York, how are you applying drug checking in clinical practice?
- 12:48And what service is that providing to both you and the clients that you work with?
- 12:53Yeah, I work in sort of two clinical environments. I work in the emergency department
- 12:57and then I work in a small clinic that's co-located within a syringe exchange.
- 13:02And so they're very different clinical environments, but I would say that I
- 13:05incorporate their information and the resources of drug checking in both situations.
- 13:11In the emergency department, I think I do a lot of bedside education with patients
- 13:14to let them know post overdose that drug checking is available for them.
- 13:18We also have kits that have naloxone available as well as test strips,
- 13:23and we hand them out to patients for free at the point of care in the ER.
- 13:28And that's for patients also who maybe haven't come in specifically for an overdose
- 13:32but report substance use as part of their medical history, such that we're really
- 13:37trying to make drug checking,
- 13:38particularly with test strips, more available to people if their access point
- 13:43to health care is even in the ER.
- 13:44In the clinic, I would say we also provide test strips, but we also have the additional resource
- 13:50of having information through the New York City programs of the FTIR drug checking.
- 13:55Well, they will come on site and check samples that have either been collected
- 13:59or submitted and do it with test strips, but also do it with GC mass spectrometry.
- 14:05And so we're able to get more detailed data.
- 14:07And I think for me, working once a week in this clinic, I appreciate that data
- 14:12because then I can report it back to my patients and try to let people know
- 14:16sort of what's maybe available or in the supply in their local community.
- 14:21Because while my ER job is in Manhattan and my clinic job is in Brooklyn.
- 14:27Those two supplies may be vastly different.
- 14:29And so I really appreciate having a wealth of resources for drug checking,
- 14:33largely so that I can pack patient education and really try and encourage people
- 14:37to engage in drug checking practices on their own to help keep them safe.
- 14:42I also, besides working in the State Department of Health, work in a clinic
- 14:46once a week, and we hand out a lot of test strips there.
- 14:49Basically, all of my patients have opioid use disorder, and that's what I'm there for.
- 14:54And there's a lot of things I appreciate about the strips, but one of them is
- 14:58simply the way it opens up conversations.
- 15:01There's lots of ways to tell my patients that I still care about them if they still use other drugs.
- 15:06I hope they know that pretty clearly by now, but we really want them to know what they're getting.
- 15:11Early on, And before fentanyl was ubiquitous, we added it to our urine drug
- 15:15tests, not as a gotcha item, but so we could tell people that they were getting fentanyl.
- 15:19We don't make big decisions most of the time on urine drug testing.
- 15:24Now I can give them the tool that they can take out into the field.
- 15:28They can give them to their friends.
- 15:30And it just makes, I think it shows a huge amount of respect for people to help
- 15:35them understand that they can make some choices about what they're getting or
- 15:40what they might get the next day. And I really like
- 15:43the level of respect that gives. Also giving them naloxone kits,
- 15:47not only it might save their life, but I think they can go out and save lives.
- 15:50So all these tools, I think, are good for them developing better senses of themselves
- 15:57having been so stigmatized as drug users for a long time.
- 16:00That's interesting. It sounds like drug checking, whether it's a mass spectrometry or just a test strip,
- 16:07it can almost act as a gateway to other services to build trust with the clients
- 16:11that you're working with and potentially have them return to care or return
- 16:15to you for other issues that they're having. What a wonderful full circle moment.
- 16:19Certainly don't want patients to be coming in on them to go see Dr.
- 16:22Stangliff that she's going to complain that I'm using drugs.
- 16:25No, we're going to see what's going on that's good.
- 16:28So I'm sure we have some listeners out there very appreciative of this information,
- 16:32just understanding what substances are out there. but some also might want a
- 16:37little more in terms of actionable resources.
- 16:40Luckily, I think both of my guests today are poised to provide them.
- 16:44Jennifer, could you kick us off? What would you recommend to a listener looking
- 16:47for more information that they can use to take action either by themselves or in clinical practice?
- 16:53That's a great question. I think that sort of in the spirit of discussing drug
- 16:58checking and drug checking resources, I think that the data that the New York
- 17:03State Department of Health provides online about drug checking,
- 17:07it's linked in the resources,
- 17:08is as real time as we can possibly get it right now in terms of letting people
- 17:14know what might be in the supply, what to look out for,
- 17:18and sort of making connections about some of these new things that they may
- 17:21have heard in other regions, and then affecting their clinical care and the
- 17:25care they provide to patients no matter what sort of setting that's in,
- 17:29whether it's in an ER or hospital or a clinic.
- 17:32I think that we, with this problem, need to try to be more proactive with our
- 17:38data and our response and less reactive.
- 17:41Trying to remind ourselves to look at the data that's out there that our epidemiologists
- 17:45and our departments of public health are putting out and screening for sort
- 17:49of in a continuous way is really the most proactive that we can be at this time.
- 17:55And I also want to let people know that whether they're in a clinic or they're
- 17:59an individual at home, they can go to Matters, which is a Buffalo program,
- 18:05which will supply them with fentanyl test strips,
- 18:09xylozine test strips, and of course, everybody at risk of seeing an overdose
- 18:13should be carrying their naloxone.
- 18:15Used mine three times on the streets of New York, all three times.
- 18:19It actually was an overdose because they came around.
- 18:21So those are things that people can do right now without having to make institutional changes.
- 18:27Institutional changes are possible, but they take some time.
- 18:30Thanks for that. In addition to the Matters Network, folks in New York can also
- 18:34order naloxone and other supplies, both from Next Distro, their online distributor.
- 18:40Provide for free these services, as well as AwaySAS.
- 18:43So all of those links, if you're interested in getting your naloxone,
- 18:46getting your test strips, getting anything else to make drug use safer,
- 18:50we do have several places where those are available here in New York.
- 18:53I want to switch gears a little bit and talk about the future.
- 18:56And I'm curious, both Dr.
- 18:58Stamcliffe and Dr. Love, what you think about the future if these programs were
- 19:03expanded statewide or potentially put into more than the six drug user health
- 19:08hubs that we have available.
- 19:09So what do you think the clinical impact would be? What would be the positive change?
- 19:14Up until recently, one of the only places we've known what people were getting
- 19:18in their drugs is primarily from autopsies and a little bit from urine drug checking.
- 19:23That would be a different world if people can know what's in their drugs,
- 19:27like they can go to the pharmacy and look at the bottle of whatever the gas
- 19:31reliever is and find out what it's actually in.
- 19:33So that would be a big change.
- 19:36And I think that we would see people change behaviors.
- 19:40Now, everybody's not going to say, oh, there's fentanyl in here,
- 19:43unless it's cocaine, and not take it.
- 19:46And that's the thing that's a misunderstanding. But people make other kinds
- 19:49of changes so we can get some concrete examples of that.
- 19:53Choosing a different supplier might be something that they might do.
- 19:57Understanding what happened to themselves might be something.
- 20:01So a lot of times people check after they use and discover that they had a really
- 20:05strange experience and avoid that experience in the future.
- 20:09Again, I think that being able to refer more people to such places shows respect
- 20:14for the patients, which I think is a key part of all this.
- 20:17So I think, and as Dr. Loves said, we can do better education with our patients
- 20:21on what's out there locally rather than looking at data from Western New York
- 20:27when you're in New York City and vice versa.
- 20:30Dr. Love, same question. What do you think will happen in New York State if
- 20:34drug checking is expanded and these services are available to everyone?
- 20:37This is a dream that I sort of have is like how to think about when I put my
- 20:43research hat on how to integrate the numerous data sources that sort of exist in separate pillars,
- 20:50but could be tremendously powerful if we were able to integrate them in real time.
- 20:55A lot of my research is focused around like the clinical effects of these novel substances.
- 21:00And so I personally pull data from resources like drug checking from laboratory
- 21:07colleagues, as well as like patient medical records.
- 21:11Those two data sources provide a lot of information. Then there are programs
- 21:14like the epidemiology programs throughout the city and the state,
- 21:18which do more surveillance and screening data, which can maybe get things in real time.
- 21:23There's data that exists from autopsies, right, and are fatal overdoses.
- 21:27There's data that I look at on social media where people, because they are able
- 21:31to be anonymous, will report in tremendous detail about their experiences or
- 21:36new drugs or new symptoms they're having.
- 21:38How could we possibly integrate all of this into a real-time type dashboard
- 21:43that myself as an ER doctor or somebody practicing in an outpatient setting
- 21:48at the start of a clinic morning could access and look at and see sort of what
- 21:52is going on and really be able to talk to patients and empower patients, as Dr.
- 21:58Stamcliffe said, with this information. I think a lot about in the ER how much
- 22:03patients still don't want to be there, patients who use drugs,
- 22:07that they still feel a lot of stigma from the healthcare setting.
- 22:10And that is certainly still pervasive at times in the ER.
- 22:14And I wonder if we had data that ER clinicians could check in real time.
- 22:19If it would open up a conversation and make it easier to enter a conversation
- 22:24with someone at the bedside, that would then sort of convey to that person, I care about you.
- 22:30I want you to come to the hospital. I want to be able to provide you care.
- 22:34This is my job. This is what I'm here to do for you. And it might help ease
- 22:38up some of this stigma and the barriers that have been in place for people who
- 22:44use drugs accessing health care.
- 22:46It's really a goal that I would have in the future. And I do think sort of integration
- 22:51of data and empowering health care providers could then help empower patients
- 22:56and create more open doors to health care for people who use drugs.
- 23:00Yeah, I'd just like to add a little bit to that. I found over the years that
- 23:04a lot of my medical colleagues are not comfortable not knowing things.
- 23:08And I think that adds to some of the distances, not knowing much about what's
- 23:12out there on the street. And the more ways that we can help them understand
- 23:15that, I think it becomes easier for them to relate to their patients and listen to them.
- 23:22Yeah, I very much agree. We spent so much time in medical school and residency
- 23:26learning about hypertension. So it's so easy to talk to somebody about their
- 23:29blood pressure or even their smoking habits, right?
- 23:32But this is such an evolving topic and a topic that people may have not gotten
- 23:37a lot of recent training or information on.
- 23:40And so that information gap, sort of closing that for healthcare clinicians,
- 23:44yeah, I agree, might really help them connect with this patient population better.
- 23:49In addition to kind of improving or tailoring clinical care for an individual
- 23:53or just empowering a clinician to know what they're talking about,
- 23:57do you think that there's room to improve public health messaging on a larger
- 24:01scale with this same data?
- 24:02Could that be used to kind of inform the public as well?
- 24:06Absolutely. I mean, as I said early on, we were testing people's urine for fentanyl
- 24:11just so we could let folks know.
- 24:13But that is not a source of data that's particularly out there for the public to see.
- 24:18Now, anybody looks into what's going on with heroin on the street,
- 24:23which there is almost none of, or pills, they can learn because the more data
- 24:28we've got about what's actually in the supply, the better off it is.
- 24:32Understanding that rare, but fentanyl can be found in cocaine at times.
- 24:37One of my patients gave test strips for fentanyl to his friend that had bought
- 24:41some cocaine, and that friend chose not to use it because it tested positive for fentanyl.
- 24:48So getting those words out there so that people know that maybe they want the
- 24:52scripts that they know and they want naloxone, they want these programs out there is key.
- 24:56I feel like we're kind of wrapping up the conversation, and I really honestly
- 24:59hope that it has been intriguing to our listeners as it has been to me.
- 25:02I'd like to wrap things up today by asking each of you, Dr.
- 25:06Stancliffe, Dr. Love, to share an example of a change that you've experienced
- 25:11or observed as a result of drug checking, or potentially, better yet,
- 25:15a positive change that a client made after accessing services.
- 25:18Sharon, similar to what you said, folks don't always decide not to take the
- 25:22drug just because it has something in it.
- 25:24What are some other examples of how people that you work with are using this
- 25:29information to change their behavior and potentially stay safer?
- 25:32Well, one of my patients a while back disclosed to me that he was selling amphetamines,
- 25:38gave him test strips, which he used, and he basically returned one of the supplies
- 25:43to a supplier saying, there's fentanyl in here. I can't sell this.
- 25:47I think that's huge. And I think there is the potential, not on a daily basis,
- 25:52not somebody that's just bought whatever dope they've got and they need to use
- 25:55it before they get dope sick, but on a broader scale, move the supply into a safer place.
- 26:02Don't want to leave out this part. I do work. I provide drug treatment to my
- 26:07patients with buprenorphine.
- 26:08But building those bridges to treatment, I think, is part of it as well.
- 26:12It's like, I don't want to be, I'm scared.
- 26:15I really need to make some changes now because I know what's out there.
- 26:19Well, and potentially building a bridge to, like you said, Dr.
- 26:21Love, to let someone know that you care, that you can be trusted,
- 26:24that you can be listened to when those scary moments do come up.
- 26:27Do you have a similar experience that you'd like to share with folks?
- 26:30Yeah, I think sort of as Dr.
- 26:33Stancliffe just mentioned, I think that encouraging
- 26:37the patients and clients that I work
- 26:39with to participate more in drug checking has moved some of them towards discussing
- 26:47treatment options because they are so concerned about the adulterants and the
- 26:54sort of continued evolution of adulterants and the supply.
- 26:57And not that we always want fear to be a motivating factor,
- 27:01but I think that additional information and some of the education based on the
- 27:06experiences of individuals in Philadelphia, where a lot of these adulterants
- 27:10have sort of been the first place and we've seen some of the more severe clinical effects,
- 27:14has really moved people to engage with me to get them started on Suboxone.
- 27:20And so I think that that has been just tremendously rewarding then to sort of
- 27:24see patients who are eager to learn about treatment options,
- 27:30eager to try treatment options, and just really protect themselves in a way
- 27:35that will prevent them from overdosing.
- 27:38Well, thank you both so much. This has been a wonderful conversation.
- 27:41Is there anything else that you'd like our listeners to take home with them as a key message today?
- 27:46Get your supplies and carry them and give them out as needed.
- 27:49I would just encourage people to really talk about this, I think,
- 27:54as we've really said over and over again, and not just necessarily talk to your
- 27:58colleagues if you're a clinician or talk to your patients, but talk to your
- 28:03friends, talk to your family,
- 28:04like, know who this could potentially affect.
- 28:08And so I think just the more we talk about this, the more we normalize it and
- 28:14the less it stays stigmatized and the more that we can affect positive change going forward.
- 28:20Well, thank you again for joining me today. I hope you both have a wonderful rest of your afternoon.
- 28:25Thank you for having us. Thank you.
- 28:27Right. All drugs carry some level of inherent danger.
- 28:32However, risk increases exponentially with an unregulated supply.
- 28:35Drugs in New York State vary by makeup and strength or potency,
- 28:39such that users are not always aware of what they're taking or how it will impact them.
- 28:44Drug checking provides information about what is in a substance,
- 28:47allowing users and clinicians alike to make better informed decisions.
- 28:51For example, referring clients to drug checking provides them with information
- 28:55and autonomy to make decisions about their use.
- 28:57At the same time, as a clinician, you can use drug checking data to inform clinical
- 29:02care and the recommendations you make for your patients.
- 29:05I hope you check out today's podcast resources to learn more or give us a call
- 29:09if you have a related clinical question you'd like to discuss with one of our experts.
- 29:13We're toll-free at 1-866-637-2342.
- 29:18Just press 5 to speak with a clinician about drug user health. Thank you for tuning in.
- 29:23Join us next time for a new episode of Conversations with CEI.
- 29:28Visit us at ceitraining.org and follow us on.
- 29:32Music.